**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 36787**

**Manuscript Type: Original Article**

***Retrospective Cohort Study***

**Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease**

Ayoub F *et al.* Risk factors for hepatic steatosis in cystic fibrosis

**Fares Ayoub, Cesar Trillo-Alvarez, Giuseppe Morelli, Jorge Lascano**

**Fares Ayoub,**Department of Medicine, University of Florida, Gainesville, FL 32608, United States

**Cesar Trillo-Alvarez,** Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL 32608, United States

**Giuseppe Morelli,** Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Florida, FL 32608, United States

**Jorge Lascano,** Department of Medicine, Adult Cystic Fibrosis Center, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL 32608, United States

**ORCID number:** Fares Ayoub (0000-0001-8559-5477); Cesar Trillo-Alvarez (0000-0001-6049-5111); Giuseppe Morelli (0000-0003-1877-5624); Jorge Lascano (0000-0002-9546-1867).

**Author contributions:** Ayoub F and Morelli G collected the data; Ayoub F analyzed the data; Ayoub F, Morelli G, Lascano J and Trillo-Alvarez C wrote the paper; Trillo-Alvarez C, Morelli G and Lascano J reviewed the paper.

**Institutional review board statement:** This study was reviewed and approved by the University of Florida Institutional Review Board (IRB201500737).

**Informed consent statement:** This was a retrospective review, the institutional review board provided a waiver of informed consent since no identifiable patient information would be collected or shared.

**Conflict-of-interest statement:** The authors declare no conflicts of interest related to this work.

**Data sharing statement:** Technical appendix, statistical code and datasets are available from the corresponding author at fares.ayoub@medicine.ufl.edu. No additional data are available other than what is included in the article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Dr. Fares Ayoub, MD,** Department of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32608, United States. fares.ayoub@medicine.ufl.edu

**Telephone:** +1-352-2650239

**Fax:** +1-352-2651107

**Received:** October 21, 2017

**Peer-review started:** October 24, 2017

**First decision:** November 23, 2017

**Revised:** December 6, 2017

**Accepted:** December 13, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate the clinical, biochemical and imaging characteristics of adult cystic fibrosis (CF) patients with hepatic steatosis as compared to normal CF controls.

## *METHODS*

We performed a retrospective review of adult CF patients in an academic outpatient setting during 2016. Baseline characteristics, genetic mutation analysis as well as laboratory values were collected. Abdominal imaging (ultrasound, computed tomography, magnetic resonance) was used to determine presence of hepatic steatosis. We compare patients with hepatic steatosis to normal controls.

## *RESULTS*

Data was collected on 114 patients meeting inclusion criteria. Seventeen patients (14.9%) were found to have hepatic steatosis on imaging. Being overweight (BMI > 25) (*P* = 0.019) and having a higher ppFEV1 (75 *vs* 53, *P* = 0.037) were significantly associated with hepatic steatosis. Patients with hepatic steatosis had a significantly higher median alanine aminotransferase level (27 *vs* 19, *P* = 0.048). None of the hepatic steatosis patients had frank CF liver disease, cirrhosis or portal hypertension. We found no significant association with pancreatic insufficiency or CF related diabetes.

## *CONCLUSION*

Hepatic steatosis appears to be a clinically and phenotypically distinct entity from CF liver disease. The lack of association with malnourishment and the significant association with higher BMI and higher ppFEV1 demonstrate similarities with non-alcoholic fatty liver disease. Long term prospective studies are needed to ascertain whether CF hepatic steatosis progresses to fibrosis and cirrhosis.

**Key words:** Cystic fibrosis liver disease; Hepatic steatosis; Non-alcoholic fatty liver disease

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Our retrospective cohort study of cystic fibrosis (CF) patients with hepatic steatosis demonstrates that hepatic steatosis in CF is associated with a higher body mass index as well as a higher percent predicted forced expiratory volume in 1 s, as compared to normal CF controls. None of our patients with hepatic steatosis exhibited evidence for advanced liver disease. Our findings are novel and demonstrate similarities between hepatic steatosis in CF and adult non-alcoholic fatty liver disease and future prospective studies are required to determine whether this steatosis may evolve into cirrhosis.

Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. *World J Hepatol* 2017; In press

**INTRODUCTION**

Cystic fibrosis (CF) is the most common fatal autosomal recessive disease in Caucasians. The majority of clinical manifestations of CF are due to a mutation of the CF transmembrane receptor (CFTR) resulting in defective chloride transport[1]. Outside of the classic pulmonary manifestations of CF, involvement of other organ systems such as the hepatobiliary and gastrointestinal system is common[2]. With improving care and increasing life expectancy, CF liver disease (CFLD) has arisen as a major cause of morbidity and mortality for CF patients. CFLD is now considered the third leading cause of death in CF patients after lung disease and transplantation complications[3]. Due to varying definitions of CFLD, its prevalence in adults has been reported to be between 3%-37%[4–6].

Biliary cirrhosis is the classic phenotypical manifestation of CFLD and is directly attributed to the underlying CFTR defect. However, the spectrum of hepatobiliary disease in CF patients is wide and ranges from asymptomatic elevations in aminotransferases, to end-stage cirrhosis and portal hypertension. Hepatic steatosis detected on imaging or biopsy is the most common hepatic manifestation, with a prevalence rate of 20%-60%[7,8]. While steatosis has classically been considered a benign condition in CF patients, the relationship between hepatic steatosis and the ultimate development of fibrosis and cirrhosis remains unclear[8,9]. In light of the increasing awareness of non-alcoholic steatohepatitis (NASH) as a major cause for cirrhosis there have been calls for the reconsideration of the importance of this clinical entity in CF patients[10].

Due to the fact that steatosis has classically been considered a benign lesion, patients with isolated steatosis are often excluded from studies on CFLD[11–13]. There has been little dedicated study of the risk factors for steatosis and the clinical characteristics of CF patients that exhibit this lesion. To better characterize patients with hepatic steatosis and ascertain the clinical characteristics and risk factors associated with this finding, we conducted a cross-sectional study of adult CF patients in an academic outpatient setting.

**MATERIALS AND METHODS**

## *Patients*

Patients enrolled at the University of Florida Adult Cystic Fibrosis Center during the year 2016 with a confirmed diagnosis of CF who were at least 18 years of age and had at least 1 year of complete follow up were eligible for inclusion in this cross-sectional analysis. Demographic, clinical, radiographic and laboratory data on patients eligible for inclusion were retrospectively collected. Patients with incomplete clinical, laboratory and/or radiological data were excluded. All patients with laboratory or imaging findings to suggest hepatic abnormalities underwent testing for chronic liver diseases including viral hepatitis, Wilson disease, autoimmune hepatitis, primary sclerosing cholangitis and alpha-1-antitrypsin deficiency. Patients found to have any of the previous diseases were excluded from the analysis. Patients with known CF liver disease based on well-accepted criteria by Debray were also excluded[8].

## *Definitions*

Diagnosis of CF was confirmed by the combination of clinical symptoms and an elevated sweat chloride ≥ 60 mmol/L or the presence of two disease-causing mutations in CF transmembrane conductance regulator gene (*CFTR*). *CFTR* mutation testing was performed by amplification of selected regions of the *CFTR* gene, followed by detection of wild-type and mutant sequences. Chronic pseudomonas colonization was defined as detection within a period of 6 mo of a minimum of three positive *P. aeruginosa* cultures, with at least 1 mo between the positive cultures[14]. Patients were considered pancreatic insufficient if they demonstrated clinical symptoms and fecal elastase values less than 200 μg/g[15]. All patients at our clinic undergo annual 2 h oral glucose tolerance testing (OGTT) and a diagnosis of CF related diabetes (CFRD) was established if the patient met standard diagnostic criteria outlined by the American Diabetes Association[16]. History of alcohol consumption was patient reported and documented in the medical chart. Patients were considered to have “any alcohol use” if they reported any amount of alcohol intake in the past 2 years. Significant alcohol intake was defined as > 21 drinks per week in men and > 14 drinks per week in women over a 2-year period[17]. Hyperlipidemia was based on documentation in the medical chart and/or elevations of total cholesterol, LDL or fasting triglyceride levels above standard laboratory cut-offs.

## *Imaging criteria for determination of hepatic steatosis*

Patients were considered to have hepatic steatosis on ultrasound if their liver demonstrated increased echogenicity as compared to the right kidney and impaired visualization of diaphragm and intrahepatic vessels[18,19]. Low hepatic attenuation on CT as compared to the spleen, or decreased T2 signal intensity on MRI were also considered to represent steatosis[20]. All previously mentioned imaging studies, have been independently validated with good sensitivity and specificity for the detection of hepatic steatosis in comparison to biopsy[21-23].

## *Testing for other forms of liver disease*

## Non-invasive markers of liver disease: We calculated the scores of three non-invasive biomarkers of hepatic fibrosis including AST-to-platelet ratio index (APRI), fibrosis-4 index (FIB-4) and the AST-to-alanine aminotransferase (ALT) ratio (AAR) (see supplementary files for formulas). These scoring systems have been heavily evaluated for use in chronic hepatitis C, hepatitis B and NASH[24-26]. Recently, criteria for the evaluation of CFLD that include the use of these non-invasive markers have been developed[27], thus we have included these scores in our analysis.

## *Statistical analysis*

Normally distributed data are presented as proportions (mean ± SD) and for variables not conforming to a normal distribution as median and interquartile range (IQR). Two-sample comparisons were by Fisher’s exact and *χ*2 tests as appropriate. For proportions, student’s *t* test was used for normally distributed variables and Mann-Whitney *U* test for other variables. Shapiro-Wilk test was used to determine normality of continuous variables. A two-sided *P-*value of < 0.05 was used to indicate statistical significance in all analyses. STATA version 13.0 (Statacorp, College Station, TX) was used for statistical analysis.

**RESULTS**

## *Basic demographics*

Of the 143 adult CF patients evaluated for inclusion, 114 met inclusion criteria. Of the 112 patients with known mutations, 57 had a homozygous *ΔF508* mutation, 47 had a heterozygous *ΔF508* mutation and 11 had other mutations. Median age at time of study was 29 years (IQR 24-35), median BMI was 20.9 kg/m2 (19.3-24.9) and median percent predicted FEV1 (ppFEV1) was 57 (36-76). Ninety-two patients were pancreatic insufficient, 80 patients were chronically colonized with Pseudomonas aeruginosa, 47 had CF related diabetes mellitus (CFRD) and 26 had a history of childhood meconium ileus.

## *Imaging findings*

Three imaging modalities (abdominal ultrasound, CT imaging, MR imaging) were used to evaluate and establish the presence of hepatic steatosis as described in the methods section. Ten patients were found to have steatosis based on ultrasound, 6 patients based on CT and 1 patient through MR imaging. Two patients demonstrated borderline splenomegaly with a spleen span of 13 cm[8]. None were found to have hepatomegaly or signs of portal hypertension.

## *Clinical features of patients with and without hepatic steatosis*

Seventeen patients (14.9%) were found to have hepatic steatosis on imaging. The clinical characteristics of patients with hepatic steatosis as compared to those without are illustrated in Table 1. Eight of the 17 patients (47%) with hepatic steatosis were overweight with a BMI > 25 kg/m2. Only being overweight (*P* = 0.019) and having a higher ppFEV­1 (75 *vs* 53, *P* = 0.037) were significantly associated with hepatic steatosis. When BMI was analyzed as a continuous variable, the significant association between higher BMI and hepatic steatosis persisted (22.3 *vs* 20.7, *P* = 0.010).

There was no significant association of hepatic steatosis with gender, age at time of study, homozygous or heterozygous ΔF508 genotype or a childhood history of meconium ileus. There was also no association with hypertension, hyperlipidemia, CFRD or any alcohol use. None of our patients had a history of significant alcohol use. None of the patients with hepatic steatosis had CF liver disease based on criteria proposed by Debray *et al*[8]. There was no association between pancreatic insufficiency and the presence of hepatic steatosis and there was no statistically significant difference in daily pancreatic enzyme replacement dosing between the two groups. There was also no significant association between being on CFTR modulator therapy and hepatic steatosis.

## *Laboratory values and non-invasive biomarkers of liver disease in patients with and without hepatic steatosis*

The laboratory values and non-invasive biomarkers of liver disease of patients with hepatic steatosis as compared to those without are illustrated Tables 2 and 3, respectively. Patients with steatosis had a significantly higher median ALT level (27 *vs* 19, *P* = 0.048), lower total bilirubin (0.3 *vs* 0.4, *P* = 0.022) and lower albumin (3.7 *vs* 4.2, *P* = 0.034). There was no significant difference between total cholesterol, LDL, HDL or triglyceride in the two groups. There was a trend towards a higher HbA1c level in hepatic steatosis patients (6.5 *vs* 6.1, *P* = 0.097). In terms of non-invasive biomarkers of liver disease, only the AAR was significantly lower in patients with hepatic steatosis (0.79 *vs* 1, *P* = 0.017). There were no significant differences in APRI or FIB-4 scores.

**DISCUSSION**

In this cross-sectional study of 114 adult CF patients, 14.9% of patients were found to have hepatic steatosis. None met widely accepted criteria for CF liver disease[8]. Hepatic steatosis was found to be significantly associated with a higher BMI as well as higher ppFEV1. Patients with steatosis had a significantly higher ALT level and a significantly lower AAR value. There was no association of hepatic steatosis with hypertension, hyperlipidemia, alcohol use or CFRD.

While CFLD manifestations such as focal and multilobular cirrhosis have been well described, hepatic steatosis in CF adults has not been well characterized in the literature. In our cohort, a higher BMI was significantly associated with hepatic steatosis and a significant proportion (47%) of our patients with hepatic steatosis were overweight with a BMI > 25 kg/m2. While the association between obesity and steatosis in non-alcoholic fatty liver disease (NAFLD) has been well-described[28], this has not been previously reported in patients with CF. Only one study in predominantly pediatric CF patients reported no association between overweight BMI and steatosis, however did not specifically include data to support that conclusion[29]. We believe that our findings may indicate a possible similarity between hepatic steatosis in CF adults and other forms of adult liver disease such as NAFLD. While it has been suggested that steatosis in CF patients may be related to alcohol use[7,9], none of our patients consumed significant amounts of alcohol. Even when considering any amount of alcohol use, we found no significant difference between patients with and without hepatic steatosis.

To further delineate possible similarities with NAFLD, we investigated the association between hepatic steatosis and classic risk factors for NAFLD including hypertension and hyperlipidemia[30]. We found no significant association with either. However, we note that our study cohort is relatively young with a low prevalence of both conditions. Another classic risk factor for NAFLD is insulin resistance and associated diabetes mellitus. We did not find a significant association between hepatic steatosis and CFRD in our cohort. While multiple authors have hypothesized that insulin resistance and CFRD are possible risk factors for hepatic steatosis in CF patients[7,31,32], our study is the first note a the lack of such an association in adult patients with hepatic steatosis.

Early studies of CFLD associated the finding of hepatic steatosis with severe malnutrition[33] while others have associated it with essential fatty acid deficiency[34]. However, it has been noted in later studies that many cases occur in patients with excellent nutritional status[7]. In our cohort, there was no significant association of steatosis with pancreatic insufficiency and the mean daily pancreatic enzyme replacement dose was similar between the two groups. This, in addition to our findings and regarding BMI above, do not support overt malnutrition as a risk factor for steatosis. Interestingly, we also found a significantly higher ppFEV1 in our hepatic steatosis group. Multiple studies have demonstrated that better nutritional status has been linked to improved pulmonary function and ppFEV1[35]. We believe that the higher BMI demonstrated in the steatosis group reflected better nutritional status and associated improved ppFEV1. Another possibility, although less likely, is that patients with overall less severe pulmonary disease and better ppFEV1 at baseline were able to maintain adequate nutrition and caloric intake leading to a higher BMI and ultimately associated hepatic steatosis.

Other risk factors for hepatic steatosis have been suggested in the literature, such as high levels of circulating cytokines in the setting of chronic infection as well as chronic antibiotic therapy[7,36]. We however found no association between chronic pseudomonas colonization (and indirectly the associated chronic antibiotic use) and hepatic steatosis. In addition, we also demonstrated a lack of association between gender or childhood meconium ileus and hepatic steatosis, both of which are classic risk factors for CFLD[37]. None of our hepatic steatosis patients met criteria for classic CFLD and none had imaging findings concerning for portal hypertension or cirrhosis. This supports the fact that hepatic steatosis in CF adults is likely phenotypically and pathophysiologically distinct from classic CFLD and possibly shares similarities with NAFLD.

Serum activities of ALT, AST and alkaline phosphatase have previously been shown to correlate with liver fibrosis in CFLD but not steatosis[29]. In one series 57% of those with steatosis detected on ultrasound had an associated elevation in aminotransferases[38]. In our cohort we found that those with hepatic steatosis only had a significantly higher ALT level as compared to those without. We found no difference in calculated non-invasive biomarkers of fibrosis including APRI and FIB-4 scores. The median AST-to-ALT ratio (AAR) in hepatic steatosis patients was < 1 and was significantly lower than patients without steatosis. This likely reflects the overall predominance of significant ALT elevation in comparison to AST elevation in our steatosis cohort. It is unclear whether this pattern is specific to CF patients with steatosis and would require validation in larger cohorts. An AAR value of ≥ 1 has been found to be predictive of cirrhosis in chronic viral hepatitis and NASH[39–41], thus routine monitoring of AAR for increasing values may be worthwhile during long term follow up of CF patients with hepatic steatosis to monitor for possible progression to fibrosis and cirrhosis.

Our study has several limitations. Our relatively small sample size and single center analysis may limit generalizability. However, we note that the University of Florida Health System is a major referral center in the southeastern United States, which increases the external validity or our results. The retrospective nature of our study only allows us to ascertain associations without determination of causality. Finally, the lack of histopathological analysis of our hepatic steatosis patients may be a relative limitation. However, it has been well-established that the clinical utility of liver biopsy is quite limited due to the patchy nature of liver disease in CF patients and liver biopsy is not routinely recommended in patients with CFLD.

Future studies may incorporate liver biopsy into their design, as well as other means of detecting insulin resistance in patients with steatosis such as homeostatic model assessment (HOMA). There have also been studies indicating significant differences in the blood levels of fatty acids and serum phospholipids between patients with CFLD and controls[42]. It would be of interest for future studies to compare such levels between patients with steatosis and controls.

In summary, in this cross-sectional analysis of adult CF patients we demonstrate a significant association between higher BMI and hepatic steatosis as detected by abdominal imaging. A trend towards higher Hba1c was also noted in patients with hepatic steatosis. We hypothesize that hepatic steatosis in adult CF patients shares similarities with NAFLD. Future, long-term prospective studies are needed to ascertain whether adult hepatic steatosis progresses to fibrosis and cirrhosis.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatic steatosis is increasingly recognized in patients with cystic fibrosis (CF) on imaging. Patients often do not demonstrate associated laboratory abnormalities or abnormal physical findings. Whether hepatic steatosis represents a manifestation of classic CF liver disease is unknown. The risk factors for such a manifestation are also unknown.

***Research motivation***

To describe the clinical characteristics of CF patients with hepatic steatosis and to describe risk factors for the condition as compared to patients with hepatic steatosis.

***Research methods***

A retrospective cohort study compares cases with hepatic steatosis to controls.

***Research results***

Our study demonstrates that CF patients with hepatic steatosis demonstrate a higher body mass index (BMI) as well as improved pulmonary function reflected by higher forced expiratory volumeas compared to normal controls. These findings indicate that patients with hepatic steatosis were relatively healthier and had an improved nutritional status as compared to controls.

***Research conclusions***

To our knowledge, this study is the first retrospective study dedicated to characterizing hepatic steatosis in adults with CF.The authors found patients with hepatic steatosis to have a higher body mass index as well as better pulmonary function. The authors did not find any patients with frank liver disease. The findings indicate similarities to non-alcoholic fatty liver disease. Whether this finding evolves into cirrhosis will need to be determined with longer prospective studies.

***Research perspectives***

CF patients with hepatic steatosis should be followed closely to determine the evolution of their disease. Caution should be exercised by providers since this lesion may exhibit similarity to non-alcoholic fatty liver disease which is now known to progress to cirrhosis in a sub-set of patients. Future, long-term prospective studies of CF patients with hepatic steatosis are needed to identify how frequently patients progress to cirrhosis.

**REFERENCES**

1 **Cheng SH**, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. *Cell* 1990; **63**: 827-834 [PMID: 1699669 DOI: 10.1016/0092-8674(90)90148-8]

2 **Gilljam M**, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. *Chest* 2004; **126**: 1215-1224 [PMID: 15486385 DOI: 10.1378/chest.126.4.1215]

3 **Kobelska-Dubiel N**, Klincewicz B, Cichy W. Liver disease in cystic fibrosis. *Prz Gastroenterol* 2014; **9**: 136-141 [PMID: 25097709 DOI: 10.5114/pg.2014.43574]

4 [CF Foundation](https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Patient-Registry-Reports/). Patient registry annual data report. Bethesda, MD, 2015

5 **Bhardwaj S**, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, Howenstine M, Kwo PY. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. *J Clin Gastroenterol* 2009; **43**: 858-864 [PMID: 19525864 DOI: 10.1097/MCG.0b013e31819e8bbd]

6 **Nash KL**, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. *J Cyst Fibros* 2008; **7**: 252-257 [PMID: 18042441 DOI: 10.1016/j.jcf.2007.10.004]

7 **Sokol RJ**, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. *J Pediatr Gastroenterol Nutr* 1999; **28** Suppl 1: S1-13 [PMID: 9934970 DOI: 10.1097/00005176-199900001-00001]

8 **Debray D**, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. *J Cyst Fibros* 2011; **10** Suppl 2: S29-S36 [PMID: 21658639 DOI: 10.1016/S1569-1993(11)60006-4]

9 **Feranchak AP**, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. *Semin Liver Dis* 2001; **21**: 471-488 [PMID: 11745036 DOI: 10.1055/s-2001-19030]

10 **Colombo C**. Liver disease in cystic fibrosis. *Curr Opin Pulm Med* 2007; **13**: 529-536 [PMID: 17901760 DOI: 10.1097/MCP.0b013e3282f10a16]

11 **Colombo C**, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. *Hepatology* 2002; **36**: 1374-1382 [PMID: 12447862 DOI: 10.1002/hep.1840360613]

12 **Feigelson J**, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. *Arch Dis Child* 1993; **68**: 653-657 [PMID: 8280210 DOI: 10.1136/ADC.68.5.653]

13 **Lindblad A**, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. *Hepatology* 1998; **27**: 166-174 [PMID: 9425933 DOI: 10.1002/hep.510270126]

14 **Cantón R**, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. *Clin Microbiol Infect* 2005; **11**: 690-703 [PMID: 16104983]

15 **O'Sullivan BP**, Baker D, Leung KG, Reed G, Baker SS, Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. *J Pediatr* 2013; **162**: 808-812.e1 [PMID: 23245194 DOI: 10.1016/j.jpeds.2012.10.008]

16 **Moran A**, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. *Diabetes Care* 2010; **33**: 2697-2708 [PMID: 21115772 DOI: 10.2337/dc10-1768]

17 **Sanyal AJ**, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011; **54**: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]

18 **Bohte AE**, Koot BG, van der Baan-Slootweg OH, van Werven JR, Bipat S, Nederveen AJ, Jansen PL, Benninga MA, Stoker J. US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents. *Radiology* 2012; **262**: 327-334 [PMID: 22106358 DOI: 10.1148/radiol.11111094]

19 **Friedrich-Rust M**, Schlueter N, Smaczny C, Eickmeier O, Rosewich M, Feifel K, Herrmann E, Poynard T, Gleiber W, Lais C, Zielen S, Wagner TO, Zeuzem S, Bojunga J. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. *J Cyst Fibros* 2013; **12**: 431-439 [PMID: 23361108 DOI: 10.1016/j.jcf.2012.12.013]

20 **Gillespie CD**, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. *Int J Hepatol* 2017; **2017**: 5128760 [PMID: 28250993 DOI: 10.1155/2017/5128760]

21 **Taylor KJ**, Gorelick FS, Rosenfield AT, Riely CA. Ultrasonography of alcoholic liver disease with histological correlation. *Radiology* 1981; **141**: 157-161 [PMID: 6270725 DOI: 10.1148/radiology.141.1.6270725]

22 **Limanond P**, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. *Radiology* 2004; **230**: 276-280 [PMID: 14695401 DOI: 10.1148/radiol.2301021176]

23 **Levenson H**, Greensite F, Hoefs J, Friloux L, Applegate G, Silva E, Kanel G, Buxton R. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. *AJR Am J Roentgenol* 1991; **156**: 307-312 [PMID: 1898804 DOI: 10.2214/ajr.156.2.1898804]

24 **McPherson S**, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010; **59**: 1265-1269 [PMID: 20801772 DOI: 10.1136/gut.2010.216077]

25 **Snyder N**, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. *J Clin Gastroenterol* 2006; **40**: 535-542 [PMID: 16825937 DOI: 10.1097/00004836-200607000-00013]

26 **Shin WG**, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, Jun SY, Park CK. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. *Dig Liver Dis* 2008; **40**: 267-274 [PMID: 18055281 DOI: 10.1016/j.dld.2007.10.011]

27 **Koh C**, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T. Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. *Hepatology* 2017; **66**: 591-601 [PMID: 28422310 DOI: 10.1002/hep.29217]

28 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

29 **Lindblad A**, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. *Hepatology* 1999; **30**: 1151-1158 [PMID: 10534335 DOI: 10.1002/hep.510300527]

30 **Rinella ME**. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015; **313**: 2263-2273 [PMID: 26057287 DOI: 10.1001/jama.2015.5370]

31 **Borowitz D**. Pathophysiology of Gastrointestinal Complications of Cystic Fibrosis. *Semin Respir Crit Care Med* 1994; **15**: 391-401 [DOI: 10.1055/s-2007-1006384]

32 **Herrmann U**, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. *Best Pract Res Clin Gastroenterol* 2010; **24**: 585-592 [PMID: 20955961 DOI: 10.1016/j.bpg.2010.08.003]

33 **Wilroy RS Jr**, Crawford SE, Johnson WW. Cystic fibrosis with extensive fat replacement of the liver. *J Pediatr* 1966; **68**: 67-73 [PMID: 5948084 DOI: 10.1016/S0022-3476(66)80423-7]

34 **Strandvik B**, Hultcrantz R. Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. *Liver* 1994; **14**: 32-36 [PMID: 8177027 DOI: 10.1111/j.1600-0676.1994.tb00004.x]

35 **Zemel BS**, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. *J Pediatr* 2000; **137**: 374-380 [PMID: 10969263 DOI: 10.1067/mpd.2000.107891]

36 **Feingold KR**, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. *Endocrinology* 1989; **124**: 2336-2342 [PMID: 2707158 DOI: 10.1210/endo-124-5-2336]

37 **Colombo C**, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, Sereni LP. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. *J Pediatr* 1994; **124**: 393-399 [PMID: 8120708]

38 **Flass T**, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. *J Cyst Fibros* 2013; **12**: 116-124 [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010]

39 **Haukeland JW**, Schreiner LT, Lorgen I, Frigstad SO, Bang C, Raknerud N, Konopski Z. ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. *Scand J Gastroenterol* 2008; **43**: 1241-1248 [PMID: 18609128 DOI: 10.1080/00365520802158614]

40 **Sheth SG**, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 1998; **93**: 44-48 [PMID: 9448172 DOI: 10.1111/j.1572-0241.1998.044\_c.x]

41 **Giannini E**, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. *Arch Intern Med* 2003; **163**: 218-224 [PMID: 12546613 DOI: 10.1001/archinte.163.2.218]

42 **Van Biervliet S**, Van Biervliet JP, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. *Clin Chem Lab Med* 2010; **48**: 1751-1755 [PMID: 20961201 DOI: 10.1515/CCLM.2010.336]

**P-Reviewer:** Cetinkunar S, Irshad M, Nicolas CT, Ong J, Ozenirler S, Roohvand F, Sharafi H **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C, C, C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Demographics of our patient sample**

|  |  |  |
| --- | --- | --- |
|  |  | Data by hepatic steatosis |
| Feature | All subjects | Hepatic steatosis | No steatosis | *P* |
| No. of patients | 114 | 17 | 97 |  |
|  Male/female | 58/56 | 9/8 | 49/48 | 0.854 |
| Median age at time of study (IQR) | 29 (24-35) | 27 | 29 | 0.981 |
| Median BMI (IQR) | 20.9 (19.3-24.9) | 22.3 | 20.7 | **0.010**a |
| Underweight (BMI < 18.5) | 19 | 2 | 17 | 0.557 |
| Overweight (BMI > 25) | 28 | 8 | 20 | **0.019a** |
| Genotype |  |  |  |  |
|  *ΔF508/ΔF508* | 57 | 11 | 46 | 0.216 |
|  *ΔF508*/other | 44 | 6 | 38 | 0.714 |
|  Other | 11 | 0 | 11 | 0.140 |
|  Unknown | 2 | 0 | 2 |  |
| ppFEV1 | 57 (36-76) | 75 | 53 | **0.037**a |
| Chronic pseudomonas colonization | 80 | 14 | 66 | 0.234 |
| Pancreatic insufficiency | 92 | 15 | 77 | 0.394 |
|  Replacement dose | 2011 (1334-2405) | 1897 | 2012 | 0.610 |
| Meconium ileus | 26 | 4 | 22 | 0.939 |
| CFRD | 47 | 4 | 43 | 0.108 |
| Hypertension | 5 | 1 | 4 | 0.561 |
| Hyperlipidemia | 12 | 1 | 11 | 0.665 |
| Any alcohol use | 42 | 8 | 34 | 0.344 |
| On CFTR modulator therapy | 29 | 6 | 23 | 0.312 |

a*P* < 0.05. IQR: Interquartile range; BMI: Body mass index; ppFEV1: Percent predicted forced expiratory volume in 1 s; CFRD: Cystic fibrosis related diabetes mellitus; CFTR: Cystic fibrosis transmembrane conductance regulator.

**Table 2 Comparison of biomarkers between patients found to have hepatic steatosis and those without steatosis on imaging**

|  |
| --- |
| Data by hepatic steatosis |
| Biomarker | Hepatic steatosis(*n* = 17, 15%) | No hepatic steatosis(*n* = 97, 85%) | *P* |
| AST | 23 (20-29) | 21 (16-26) | 0.284 |
| ALT | 27 (19-36) | 19 (13-32) | **0.048a** |
| ALP | 103 (75-120) | 99 (73-150) | 0.793 |
| Platelets | 279 (244-311) | 270 (207-342) | 0.764 |
| Total bilirubin | 0.3 (0.3-0.4) | 0.4 (0.2-0.5) | **0.022a** |
| INR | 1 (1-1.1) | 1 (1-1.1) | 0.350 |
| Albumin | 3.7 (3.5-4.2) | 4.2 (3.8-4.4) | **0.034a** |
| LDL | 78.5 (44-89) | 63.5 (45-81) | 0.424 |
| HDL | 36.5 (31-42) | 45 (36-56.5) | 0.091 |
| Triglycerides | 78.5 (65-96) | 80.5 (62-114.5) | 0.756 |
| Total cholesterol | 124.5 (93-152) | 133 (103-162.5) | 0.819 |
| HbA1c | 6.5 (5.8-7.1) | 6.1 (5.5-6.7) | 0.097 |

a*P* < 0.05. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; INR: International normalized ratio; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; HbA­1c: Hemoglobin A­1c.

**Table 3 Comparison of non-invasive biomarkers of hepatic fibrosis between patients found to have hepatic steatosis and those without steatosis on imaging**

|  |
| --- |
| Data by hepatic steatosis |
| Biomarker | Hepatic steatosis(*n* = 17, 15%) | No hepatic steatosis(*n* = 97, 85%) | *P* |
| APRI | 0.28 (0.14-0.27) | 0.19 (0.12-0.32) | 0.579 |
| FIB-4 | 0.49 (0.35-0.67) | 0.57 (0.36-0.82) | 0.629 |
| AAR | 0.79 (0.65-1.08) | 1 (0.82-1.33) | **0.017a** |

a*P* < 0.05. APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis 4 score; AAR: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio.